3 results
Approved WMOCompleted
The main objectives are to investigate the pharmacokinetic properties of DP tobramycin via the Cyclops® at different dosages in children with CF, together with the local tolerability.
Approved WMOCompleted
Primairy objective: Validating of nerve fiber length, nerve fiber density, nerve fiber branches and tortuosity of a healthy control group, sarcoidosis patients with small fiber neuroapthy and sarcoidosis patients without small fiber neuropathy.…
Approved WMORecruiting
The objectives of this are to establish the safety, tolerability, and efficacy of VRDN-001, and the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of VRDN-001 in HV and TED patients over a dose range of 3.0 to 20.0 mg/kg.